mitomycin / Generic mfg. - LARVOL DELTA

HIPEC, Hope for Cure? (IASGO 2026) - "However,recent phase III randomized trials evaluating a 30-minute Oxaliplatin HIPEC protocol—PRODIGE 7, COLOPEC,and PROPHYLOCHIP—shocked the oncology community by failing to show survival benefits...Additionally, to bypass acquired resistance, the field is standardizing tosystemic-naive, high-dose Mitomycin C (MMC ≥25 mg) for 90 minutes; a 2,093-patient registry study in BJS Open2024 proved that sub-therapeutic dosing is useless, whereas high-dose MMC significantly improves recurrence-free survival. Reassuringly, quality-of-life analyses from CAIRO6 demonstrate that while patients experiencetransient post-surgical decline, their physical and global functioning completely returns to baseline at one year.Looking forward, the integration of circulating tumor DNA (ctDNA) monitoring via trials like PREDATOR will allowclinicians to detect microscopic recurrence far earlier and match patients with genomic-targeted therapies.Ultimately, the hope for a cure does not rely on a..."

Colorectal Cancer • Microsatellite Instability • Solid Tumor • BRAF • MSI

MOONRISE-1: PHASE 3 STUDY OF TAR-210, AN ERDAFITINIB INTRAVESICAL TARGETED RELEASING SYSTEM, VERSUS INTRAVESICAL CHEMOTHERAPY IN PATIENTS WITH FGFR-ALTERED INTERMEDIATE-RISK NON–MUSCLE-INVASIVE BLADDER CANCER (SUO 2024) - P3 | "MoonRISe-1 (NCT06319820) is an open-label, multicenter, phase 3, randomized study evaluating the efficacy and safety of TAR-210 versus investigator's choice of intravesical mitomycin C or gemcitabine in patients with FGFR -altered IR NMIBC. As of August 1, 2024, 9 patients have been randomized, and recruitment is ongoing at ≈70 sites. "

Clinical • P3 data • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • Urology • FGFR

Hyperthermic Mitomycin C in Intermediate-risk Non-muscle-invasive Bladder Cancer: Results of the HIVEC-1 Trial. (PubMed, Eur Urol Oncol) - "Four-month adjuvant hyperthermic MMC using the COMBAT system for 30 and 60 min in IR-NMIBC is well tolerated, but we did not find it to be superior to normothermic MMC at 24 mo."

Journal • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • Urology • Urothelial Cancer

THOR-2 cohort 1: Results of erdafitinib (ERDA) vs intravesical chemotherapy (chemo) in patients (pts) with high-risk non–muscle-invasive bladder cancer (HR NMIBC) with select fibroblast growth factor receptor alterations (FGFRALT) who received prior bacillus calmette-guérin (BCG) treatment (ESMO 2023) - P2 | "Methods Adult pts with recurrent, BCG-treated, papillary-only HR NMIBC (high-grade Ta/T1) and select FGFRalt refusing/ineligible for RC were randomized 2:1 to 6 mg oral erda or investigator's choice of intravesical chemo (mitomycin C or gemcitabine). Conclusions Erda prolonged RFS compared with chemo in pts with papillary-only HR NMIBC with FGFRalt who had recurrence after BCG tx. Erda toxicity was generally consistent with the known safety profile of oral FGFR inhibitors."

Clinical • Late-breaking abstract • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • Urothelial Cancer • FGFR

Perioperative systemic therapy versus surgery alone for resectable colorectal peritoneal-only metastases (CAIRO6): a randomised, open-label, phase 3 trial. (PubMed, Lancet Oncol) - P2/3 | "Perioperative systemic therapy cannot be recommended in all patients with resectable colorectal peritoneal-only metastases."

Clinical • Journal • P3 data • Cardiovascular • Colorectal Adenocarcinoma • Colorectal Cancer • Diabetes • Hematological Disorders • Hypertension • Neutropenia • Oncology • Peritoneal Cancer • Solid Tumor

Two-year outcomes of PRESERFLO MicroShunt implantation in a real-world heterogeneous glaucoma cohort: a retrospective single-center study. (PubMed, Front Ophthalmol (Lausanne)) - "Complete success rates were 60.2% (year 1) and 52.0% (year 2). PreserFlo implantation provided sustained mid-term IOP reduction with substantial medication sparing and stable BCVA."

Heterogeneity • Journal • Real-world evidence • Retrospective data • Glaucoma • Ophthalmology

Intraocular Mitomycin-C in the Management of Recurrent Retinal Detachment and Proliferative Vitreoretinopathy: A Comparative Study With a Control Group. (PubMed, Retina) - "Although MMC use was associated with more favorable anatomical outcomes and complication profiles in recurrent RRD cases, the lack of statistical significance warrants cautious interpretation, and larger prospective studies are needed to confirm its potential benefit as an adjuvant therapy."

Journal • Retinal Disorders

Efficacy and Safety of Intraoperative Hyperthermic Intraperitoneal Chemotherapy for Locally Advanced Colon Cancer: A Phase 3 Randomized Clinical Trial. (PubMed, JAMA Surg) - P3 | "Patients were randomly assigned 1:1 to receive cytoreduction plus HIPEC with mitomycin C (30 mg/m2 over 60 minutes; investigational group) or cytoreduction alone (comparator group), both followed by systemic adjuvant chemotherapy...This approach should be considered for patients with locally advanced colorectal cancer. ClinicalTrials.gov Identifier: NCT02614534."

Clinical • Journal • Metastases • P3 data • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

Feasibility and safety results from RAD-IO: A multi-stage trial of durvalumab with chemoradiotherapy with 5-fluorouracil and mitomycin C in patients with muscle-invasive bladder cancer. (ASCO 2026) - "Durvalumab combined with CRT demonstrated promising 1-year DFS and survival outcomes compared to our previously reported CRT outcomes (Hall, E., et al, 2022) with manageable safety profile. CRT-D is a safe treatment with a side effect profile in keeping with known side effects of CRT and durvalumab. Further investigation is warranted."

Clinical • Bladder Cancer • Genito-urinary Cancer • Infectious Disease • Nephrology • Oncology • Solid Tumor • Urothelial Cancer

Mitomycin plus BCG as adjuvant intravesical therapy for high-risk, non–muscle-invasive bladder cancer: A randomized phase 3 trial (ANZUP 1301). (ASCO 2025) - P3 | "BCG+MM had similar efficacy and safety, but with fewer treatment discontinuations and fewer doses of BCG than BCG-alone. BCG+MM is a good alternative to BCG-alone."

Clinical • Late-breaking abstract • P3 data • Bladder Cancer • Fatigue • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • Urothelial Cancer

DNA polymerase I is required for the Hachiman-family anti-phage defense system. (PubMed, J Bacteriol) - "In a temperature-sensitive polA mutant (polA12), AbpAB- and HamAB-mediated restriction of multiple phages was lost, as was AbpAB-dependent growth arrest triggered by mitomycin C (MMC)-induced DNA damage or by expression of the T4 single-stranded DNA-binding protein gp32...In contrast, deleting rnhA (encoding RNase HI) makes AbpAB expression toxic even in the absence of phage. These results show that host replication and repair enzymes can both support anti-phage defense and prevent Abi-associated growth inhibition during uninfected growth."

Journal • Infectious Disease • RPA1

Feasibility and safety results from RAD-IO: A multi-stage trial of durvalumab (Medi4736) with chemoradiotherapy with 5-fluorouracil and mitomycin C in patients with muscle-invasive bladder cancer. (ASCO-GU 2025) - "The schedule of neo-adjuvant, synchronous and adjuvant durvalumab was deliverable with full dose CRT to bladder. Most participants completed CRT as planned, none discontinued Durva due to toxicity, only 3 incurred toxicity related delays but continued treatment."

Clinical • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor

Evaluation of Immediate Preoperative Instillation (IPOI) of Mitomycin C Compared to Early Postoperative Instillation (IPOP) in Non-muscle Invasive Bladder Cancer (clinicaltrials.gov) - P=N/A | N=60 | Completed | Sponsor: Poitiers University Hospital | Unknown status ➔ Completed | Phase classification: P2 ➔ PN/A

Phase classification • Trial completion • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor

Type A acute aortic dissection associated with 5-fluorouracil: A rare but serious vascular toxicity. (PubMed, Bull Cancer) - "We report the case of a 78-year-old patient treated for muscle-invasive urothelial bladder carcinoma (pT2) with a trimodality approach including macroscopically complete transurethral resection of the bladder, followed by concurrent chemoradiotherapy with mitomycin C and 5-FU. Although a causal relationship cannot be formally established, the temporal association and the absence of an alternative cause support a possible role of 5-FU. This case highlights the need to promptly consider aortic dissection in patients presenting with unusual chest or back pain occurring under fluoropyrimidine therapy."

Journal • Back Pain • Bladder Cancer • Cardiovascular • Genito-urinary Cancer • Musculoskeletal Pain • Oncology • Pain • Solid Tumor

Bladder Preservation or Cystectomy for MIBC (clinicaltrials.gov) - P1 | N=20 | Active, not recruiting | Sponsor: Dana-Farber Cancer Institute

New P1 trial • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • Urothelial Cancer

Isolation, Purification, and Characterization of Leptophages. (PubMed, Methods Mol Biol) - "Consequently, some laboratories attempt to isolate leptophage particles from environmental samples or from bacterial cultures following mitomycin C induction. Here, we present several procedures for isolating, purifying, and characterizing bacteriophages based on the leptophages characterization protocols."

Journal

Coblation in the Treatment of Isolated Subglottic Stenosis (AAO-HNSF 2026) - "Of 33 total surgeries, the following techniques were used: Coblation (n=23, 69.7%), steroid injection (n=27, 81.8%), mitomycin (n=28, 84.8%), and balloon dilation (n=32, 97.0%)... Coblation is effective to lyse scar bands radially or perform segmental resection of scar to maintain patency of the subglottic airway. Future studies are needed to compare coblation to other techniques such as CO2 laser or balloon dilation alone."

Immunology

Efficacy and Safety of Disitamab Vedotin Combined with Intravesical Instillation Mitomycin-C in Patients with HER2-Expressing High-Risk Non–Muscle- Invasive Bladder Cancer: A Phase II Study (ESMO 2026) - No abstract available

Clinical • P2 data • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • HER-2

Early outcomes of the PLATO ACT5 randomised trial: Personalizing anal cancer radiotherapy dose. (ASCO-GI 2026) - "Pts were randomised 1:1:1 in 28 fractions to standard dose IMRT (sd-IMRT; 53.2Gy), de1-IMRT (58.8Gy) or de2-IMRT (61.6 Gy) with concurrent mitomycin 12mg/m2 day (D) 1 & capecitabine (CAP) 825mg/m2 BD on RT days or 5FU 1000mg/m2 D1-4 & D29-32... Dose escalation has similar toxicity, but does not improve early outcomes. Further stage stratification and novel biology approaches for personalisation are needed."

Clinical • Anal Carcinoma • Gastrointestinal Cancer • Oncology • Solid Tumor

Conjunctival Melanocytic Lesions: A Practical Sequential Treatment Approach. (PubMed, Ophthalmology) - "A tailored sequential multimodal approach achieved satisfactory local disease control, with local recurrence being primarily driven by non-bulbar involvement and residual pigmentation after primary therapy, while metastatic spread was strongly associated with ulcerative features, followed by non-bulbar involvement and tumour thickness."

Journal • Eye Cancer • Melanoma • Ocular Melanoma • Oncology • Solid Tumor

Safety and Efficacy of PIPAC Using Single Agent Mitomycin in Solid Tumors (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Not yet recruiting ➔ Recruiting

Enrollment open • Gastrointestinal Cancer • Oncology • Peritoneal Cancer • Solid Tumor

Mitomycin-Associated Pulmonary Veno-Occlusive Disease Following Chemoradiation: A Cardio-Oncology Case Treated with Sotatercept (AHA 2026) - "Abstract is embargoed at this time."

Clinical • Cardiovascular • Hepatology

Hypoxic bladder cancers have a poorer outcome following hypofractionated vs conventionally fractionated radiotherapy in the BC2001 and BCON randomised trials (ESMO 2022) - "The BC2001 trial showed combining chemotherapy (5-FU, mitomycin-C) with radiotherapy (RT) improves loco-regional progression free survival...Conclusions Hypoxic MIBC has a poor prognosis and exhibits fraction sensitivity, which is mitigated with hypoxia modification. Use of hypoxia score to personalise treatment needs testing in a biomarker-stratified trial."

Clinical • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • Urothelial Cancer

MoonRISe-3: a phase 3 study of erda-iDRS, an erdafitinib intravesical drug-releasing system, vs intravesical chemotherapy in patients with bacillus Calmette-Guérin–treated high-risk non–muscle-invasive bladder cancer with susceptible FGFR alterations (AUA 2026) - P3 | "Approximately 220 patients will be randomized 1:1 to receive erda-iDRS or investigator's choice of either IVES mitomycin C (MMC) or gemcitabine. The first patient was enrolled in Nov 2025. As of Jan 21, 2026, ∼120 patients have been screened, and recruitment is ongoing at ∼100 sites worldwide."

Clinical • P3 data • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • FGFR

Comparative analysis of platinum nanoparticles interactions with Mitomycin C and its activated metabolite. (PubMed, Biomed Pharmacother) - "As PtNPs alone affected metabolic activity at higher concentrations, the combination effects cannot be attributed solely to enhancement of MMC activity. These findings support further investigation of PtNPs as modulators of mitomycin-related compounds, although their mechanisms and therapeutic relevance require additional validation."

Journal • Cardiovascular • Oncology